Highlights for the second quarter of the 2026 fiscal year. Operating revenue was 103,732 thousand yen, net income for the period was -787,591 thousand yen. R&D costs were 368,318 thousand yen, SG&A expenses were 549,655 thousand yen. The latest quarter’s revenue is included as a component, and YoY comparison and segment information are included in the financial statements summary.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"MediciNova, Inc.\uff08\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u30fb\u30a4\u30f3\u30af\uff09","jir_importance":"\u2605\u2605\u2605\u2605","jir_publication_date":"2026-09-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4875-20260911-01.pdf","jir_short_summary":"Highlights for the second quarter of the 2026 fiscal year. Operating revenue was 103,732 thousand yen, net income for the period was -787,591 thousand yen. R&D costs were 368,318 thousand yen, SG&A expenses were 549,655 thousand yen. The latest quarter's revenue is included as a component, and YoY comparison and segment information are included in the financial statements summary.","jir_summary":"### Summary of Results\nIn this interim period, revenue is recorded at 103,732 thousand yen while operating income is -864,190 thousand yen and net income is -787,591 thousand yen. The largest cost items are SG&A (549,655 thousand yen) and R&D\/Patent costs (368,318 thousand yen), with continued R&D investment. Although currently in a loss, continued R&D investment is emphasized, and progress in clinical trials and pipeline advancement is expected to help improve future cash flows.\n\n### Outlook and Initiatives\nThe financial highlights also note the progress of major clinical programs, with ongoing development of MN-166, MN-001, etc. The timing of topline data disclosure and data analysis completion is limited to certain sections, and future approval prospects depend on these data analysis results. On the financial side, investors are likely to focus on cash and cash equivalents movements, funding options, and progress of cost-containment measures.","jir_financial_highlights":"Operating Revenue: 103,732\u5343\u5186 (Year-over-year not available)\nOperating Income: -864,190\u5343\u5186 (Year-over-year not available)\nNet Income: -787,591\u5343\u5186 (Year-over-year not available)\nR&D\uff0fPatent Costs: 368,318\u5343\u5186 (Breakdown for the cumulative second quarter)\nSG&A: 549,655\u5343\u5186 (Breakdown for the cumulative second quarter)","jir_category":"","jir_hashtags":"#MediciNova, #Financial, #Interim, #R&DInvestment, #MN166, #MN001","jir_key_figures":"Operating Revenue: 103,732\u5343\u5186\nOperating Income: -864,190\u5343\u5186\nNet Income: -787,591\u5343\u5186","jir_meta_title":"\u3010MediciNova, Inc.\u3011Financial Highlights\uff5c2026 Fiscal Year 2Q (Interim)","jir_meta_description":"Summary of MediciNova's 2026 fiscal year second quarter results. Covers revenue, cost structure, net income, breakdown of R&D and SG&A, and implications of future clinical development progress.","jir_og_title":"MediciNova\uff5cFinancial Highlights (2Q)","jir_og_description":"MediciNova's 2026 fiscal year second quarter financial snapshot. Focus on revenue, loss drivers, and R&D costs; attention on future clinical development progress and capital strategy.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-112620","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n